Since Syk and Btk showed important regulation of both BcR and FcR signaling, specific pharmacological inhibitors for these kinases are currently undergoing preclinical and clinical trials as treatment for autoimmune diseases and hematological cancers. Here, BCR is linked to autoimmune disease.